A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia


Study SPR001-203 will be a larger, randomized, double-blind, placebo-controlled, dose-ranging study that will investigate the efficacy and safety of up to 52 weeks of treatment with tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline (A4 >1.5x upper limit of normal [ULN] and ACTH >2x ULN) on their current Glucocorticoid regimen.

I'm interested

This study is NOT accepting healthy volunteers

Congenital Adrenal Hyperplasia

Adrenal Disorder, CAH, Congenital Adrenal Hyperplasia

Kristin Boxwell -
Kyriakie Sarafoglou
Phase III
See this study on